REGENERX BIOPHARMACEUTICALS INC
RGRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RGRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2023.
Tracking 3 pipeline candidates · 1 clinical trial for REGENERX BIOPHARMACEUTICALS INC.
Run REGENERX BIOPHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REGENERX BIOPHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
1.7 months
OCF -$189K · Net income -$385K
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of Apr 29, 2026- % of float
- 0.1%
- Days to cover
- 0.2
- Shares short
- 191
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RGRX short interestFrequently asked questions
What is REGENERX BIOPHARMACEUTICALS INC's lead drug candidate?
REGENERX BIOPHARMACEUTICALS INC's most advanced tracked candidate is rgn-137 (Phase 3) for Dermal wounds, reduction of scar tissue, and epidermolysis bullosa.
Who is the CEO of REGENERX BIOPHARMACEUTICALS INC?
Mr. J. J. Finkelstein is the chief executive officer of REGENERX BIOPHARMACEUTICALS INC (RGRX).
Where is REGENERX BIOPHARMACEUTICALS INC headquartered?
REGENERX BIOPHARMACEUTICALS INC (RGRX) is headquartered in Rockville, MD, United States.
What therapeutic areas does REGENERX BIOPHARMACEUTICALS INC focus on?
REGENERX BIOPHARMACEUTICALS INC develops therapies across Gene Therapy, Ophthalmology, Cardiovascular, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.